Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nitric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1186050 | 0.88 | NPC1 (0.59) | MAPTNPC1SMN1; SMN2RAB9AGAA | |
| Hydrochloric Acid SCHEMBL3977693 | 0.86 | NPC1 (0.57) | MAPTNPC1SMN1; SMN2RAB9AGAA | |
| Bicarbonate SCHEMBL3975933 | 0.85 | RAB9A (0.61) | ALDH1A1MAPTNPC1SMN1; SMN2RAB9A | |
| Nitric Acid SCHEMBL1183979 | 0.84 | PLAU (0.49) | ALDH1A1MAPTNPC1SMN1; SMN2RAB9A | |
| Nitric Acid SCHEMBL1363033 | 0.82 | PLAU (0.54) | ALDH1A1MAPTNPC1SMN1; SMN2RAB9A | |
| Nitric Acid SCHEMBL9982936 | 0.81 | LMNA (0.49) | ALDH1A1MAPTNPC1SMN1; SMN2RAB9A | |
| Nitric Acid SCHEMBL1185356 | 0.81 | ALOX5 (0.56) | ALDH1A1MAPTNPC1SMN1; SMN2RAB9A | |
| Nitric Acid SCHEMBL6034752 | 0.81 | ALOX5 (0.56) | ALDH1A1MAPTNPC1SMN1; SMN2RAB9A | |
| Nitric Acid SCHEMBL2073717 | 0.80 | KMT2A (0.50) | ALDH1A1MAPTSMN1; SMN2RAB9AHPGD | |
| Nitric Acid SCHEMBL27720595 | 0.80 | IDO1 (0.60) | ALDH1A1MAPTNPC1SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7160897-B2 | Therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| US-7087618-B2 | Pyrazolopyridinyl pyrimidine therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-08 | — | — | US | disclosed |
| US-20050182080-A1 | Therapeutic compounds | CHAMBERLAIN STANLEY D (US) | 2005-08-18 | — | — | US | disclosed |
| EP-1341788-B1 | PYRAZOLOPYRIDINES | GLAXO GROUP LTD (GB) | 2005-08-10 | — | — | EP | disclosed |
| US-20050171133-A1 | Therapeutic compounds | CHAMBERLAIN STANLEY D (US) | 2005-08-04 | — | — | US | disclosed |
| US-6919352-B2 | Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-19 | — | — | US | disclosed |
| US-20040072853-A1 | Therapeutic compounds | CHAMBERLAIN STANLEY D (US) | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072853-A1 | Therapeutic compounds | PCSK9, ABCB1, FURIN | ALDH1A1 168/4885MAPT 797/4885NPC1 21/4885 |
| US-20050182080-A1 | Therapeutic compounds | PCSK9, FURIN, CYP11B2 | ALDH1A1 207/4885MAPT 815/4885NPC1 27/4885 |
| US-20050171133-A1 | Therapeutic compounds | PCSK9, FURIN, CYP11B2 | ALDH1A1 207/4885MAPT 815/4885NPC1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.